| Literature DB >> 29496984 |
Sophie Poty1, Lynn C Francesconi2,3, Michael R McDevitt1,4, Michael J Morris5, Jason S Lewis6,7.
Abstract
The use of radioactive sources to deliver cytotoxic ionizing radiation to disease sites dates back to the early 20th century, with the discovery of radium and its physiologic effects. α-emitters are of particular interest in the field of clinical oncology for radiotherapy applications. The first part of this review explored the basic radiochemistry, high cell-killing potency, and availability of α-emitting radionuclides, together with hurdles such as radiolabeling methods and daughter redistribution. The second part of this review will give an overview of the most promising and current uses of α-emitters in preclinical and clinical studies.Keywords: clinical trials; radiochemistry; radiotherapy; α-emitters
Mesh:
Year: 2018 PMID: 29496984 DOI: 10.2967/jnumed.117.204651
Source DB: PubMed Journal: J Nucl Med ISSN: 0161-5505 Impact factor: 10.057